Guggenheim Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $44

Benzinga · 10/08 09:55
Guggenheim analyst Seamus Fernandez initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $44.